Timothy D. Wiltshire, Ph.D.

  1. Cable J, Saphire EO, Hayday AC, Wiltshire TD, Mousa JJ, Humphreys DP, Breij ECW, Bruhns P, Broketa M, Furuya G, Hauser BM, Mahevas M, Carfi A, Cantaert T, Kwong PD, Tripathi P, Davis JH, Brewis N, Keyt BA, Fennemann FL, Dussupt V, Sivasubramanian A, Kim PM, Rawi R, Richardson E, Leventhal D, Wolters RM, Geuijen CAW, Sleeman MA, Pengo N, Donnellan FR. Antibodies as drugs-a Keystone Symposia report. Ann N Y Acad Sci. 2023 Jan; 1519 (1):153-166 Epub 2022 Nov 16
    View PubMed
  2. Li M, Beck EJ, Laeyendecker O, Eby Y, Tobian AAR, Caturegli P, Wouters C, Chiklis GR, Block W, McKie RO, Joyner MJ, Wiltshire TD, Dietz AB, Gniadek TJ, Shapiro AJ, Yarava A, Lane K, Hanley DF, Bloch EM, Shoham S, Cachay ER, Meisenberg BR, Huaman MA, Fukuta Y, Patel B, Heath SL, Levine AC, Paxton JH, Anjan S, Gerber JM, Gebo KA, Casadevall A, Pekosz A, Sullivan DJ. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Adv. 2022 Jun 28; 6 (12):3678-3683
    View PubMed
  3. Wiltshire TD, Deeds MC, Radel DJ, Bornschlegl AM, Schmidt CS, Thebiay JM, Pelleymounter LL, Jacob EK, Stubbs JR, Gastineau DA, Dietz AB. Management of externally manufactured cell therapy products: the Mayo Clinic approach. Cytotherapy. 2022 Jan; 24 (1):19-26 Epub 2021 June 02
    View PubMed
  4. Wiltshire TD, Milosevic D, Jacob EK, Grebe SK, Dietz AB. Sensitive detection of integrated and free transcripts in chimeric antigen receptor T-cell manufactured cell products using droplet digital polymerase chain reaction. Cytotherapy. 2021 May; 23 (5):452-458 Epub 2021 Mar 11
    View PubMed
  5. Wiltshire T, Ducy M, Foo TK, Hu C, Lee KY, Belur Nagaraj A, Rodrigue A, Gomes TT, Simard J, Monteiro ANA, Xia B, Carvalho MA, Masson JY, Couch FJ. Functional characterization of 84 PALB2 variants of uncertain significance. Genet Med. 2020 Mar; 22 (3):622-632 Epub 2019 Oct 21
    View PubMed
  6. Murphy SJ, Hart SN, Halling GC, Johnson SH, Smadbeck JB, Drucker T, Lima JF, Rohakhtar FR, Harris FR, Kosari F, Subramanian S, Petersen GM, Wiltshire TD, Kipp BR, Truty MJ, McWilliams RR, Couch FJ, Vasmatzis G. Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease. Cancer Res. 2016 Feb 1; 76 (3):749-61 Epub 2015 Dec 16
    View PubMed
  7. Singh N, Basnet H, Wiltshire TD, Mohammad DH, Thompson JR, Heroux A, Botuyan MV, Yaffe MB, Couch FJ, Rosenfeld MG, Mer G. Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1. Proc Natl Acad Sci U S A. 2012 Sep 4; 109 (36):14381-6 Epub 2012 Aug 20
    View PubMed
  8. Singh N, Wiltshire TD, Thompson JR, Mer G, Couch FJ. Molecular basis for the association of microcephalin (MCPH1) protein with the cell division cycle protein 27 (Cdc27) subunit of the anaphase-promoting complex. J Biol Chem. 2012 Jan 20; 287 (4):2854-62 Epub 2011 Dec 02
    View PubMed
  9. Wiltshire TD, Lovejoy CA, Wang T, Xia F, O'Connor MJ, Cortez D. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J Biol Chem. 2010 May 7; 285 (19):14565-71 Epub 2010 Mar 15
    View PubMed
  10. Wiltshire T, Senft J, Wang Y, Konat GW, Wenger SL, Reed E, Wang W. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven. Mol Pharmacol. 2007 Apr; 71 (4):1051-60 Epub 2007 Jan 17
    View PubMed
  11. Wang Y, Wiltshire T, Senft J, Reed E, Wang W. Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochem Pharmacol. 2007 Feb 15; 73 (4):469-80 Epub 2006 Oct 27
    View PubMed
  12. Wang Y, Wiltshire T, Senft J, Wenger SL, Reed E, Wang W. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Mol Cancer Ther. 2006 Dec; 5 (12):3153-61
    View PubMed
  13. Wang J, Wiltshire T, Wang Y, Mikell C, Burks J, Cunningham C, Van Laar ES, Waters SJ, Reed E, Wang W. ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol Chem. 2004 Sep 17; 279 (38):39584-92 Epub 2004 July 20
    View PubMed